In recent studies, treatment of NSCLC with PCA has been shown to inhibit FAK, MAPK, and NF-κB gene expressions, resulting in decreased production of cytokines and growth factors, thus preventing NSCLC cell proliferation4,5. The gene discussed is PTK2; the disease is non-small cell lung carcinoma.